Gradient is developing a novel catheter-based technology to cure pulmonary hypertension.
Pulmonary hypertension represents a huge, unmet clinical need. It is a uniformly fatal condition affecting 500,000 patients per year worldwide. Gradient’s disruptive therapy is based on proven clinical, human data and results in an unprecedented reduction in pulmonary vascular resistance. Through improvement in cardiovascular hemodynamics, hospitalization rates, and costs of care, it has breakthrough potential as a life-saving treatment and a potential cure for an otherwise fatal disease.
The current FDA-approved drugs are only indicated for a small percentage of patients, yet this drug market represents a $2B opportunity in America alone. Our approach would allow these patients to come off of their medications, relieving this financial burden.